ADMA Biologics
ADMA
160 hedge funds and large institutions have $592M invested in ADMA Biologics in 2022 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 54 increasing their positions, 38 reducing their positions, and 8 closing their positions.
705% more call options, than puts
Call options by funds: $11.2M | Put options by funds: $1.39M
413% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 8
88% more capital invested
Capital invested by funds: $315M → $592M (+$277M)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
42% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 38
23% more funds holding
Funds holding: 130 → 160 (+30)
4% more ownership
Funds ownership: 66.09% → 70.09% (+4%)
Top Buyers
| 1 |
Millennium Management
New York
|
+$11M |
| 2 |
D.E. Shaw & Co
New York
|
+$8.22M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.02M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$6.94M |
| 5 |
BlackRock
New York
|
+$6.56M |
Top Sellers
| 1 |
BFM
Boothbay Fund Management
New York
|
-$21.8M |
| 2 |
CC
Clearline Capital
New York
|
-$6.07M |
| 3 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$3.91M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.55M |
| 5 |
FAM
Fred Alger Management
New York
|
-$2.58M |
ADMA Hedge Fund Activity: Q4 2022 in Review
160 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q4 2022, worth a combined $592M — up 88% from $315M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new ADMA positions and 8 closed out — a net gain of 33 holders — while 54 added to existing stakes and 38 trimmed.
The largest buyer was Millennium Management, adding an estimated $11M. The largest seller was Boothbay Fund Management, cutting an estimated $21.8M.
- 160 institutional investors held ADMA Biologics (ADMA) as of Q4 2022, up from 130 in Q3 2022.
- Funds reported $592M of ADMA Biologics stock for Q4 2022, up 88% quarter-over-quarter.
- 41 funds opened new ADMA Biologics positions in Q4 2022 and 8 closed out, a net change of +33 holders.
- The largest ADMA Biologics buyer in Q4 2022 was Millennium Management, an estimated $11M added.
- The largest ADMA Biologics seller in Q4 2022 was Boothbay Fund Management, an estimated $21.8M sold.
Based on aggregated 13F filings for Q4 2022.